skip to main content

Early Biologic Use in SLE — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateSLE & Antiphospholipid SyndromeEarly Biologic Use in SLESCE Rheumatology

A 28-year-old woman has active extrarenal systemic lupus erythematosus despite adherence to hydroxychloroquine. Attempts to reduce prednisolone below 10 mg daily have caused recurrent inflammatory arthritis and rash. She has not previously received methotrexate, azathioprine or mycophenolate. According to the 2023 EULAR recommendations, which statement best describes the sequencing of biological therapy in this situation?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Belimumab or anifrolumab may be added without requiring prior treatment with a conventional immunosuppressive drug

EULAR recommends considering an immunosuppressive drug and/or a biological agent—belimumab or anifrolumab—when extrarenal SLE is inadequately controlled by hydroxychloroquine or glucocorticoids cannot be reduced to an acceptable maintenance dose. Prior exposure to methotrexate, azathioprine or mycophenolate is therefore not mandatory before adding one of these biologics. This is not equivalent to using biologics as unrestricted first-line treatment at diagnosis: the patient should have an indication for treatment escalation, as demonstrated here by persistent activity and steroid dependence. Options B and D invent requirements for a specified number or duration of conventional therapies. Rituximab is generally considered for refractory disease, so C reverses the EULAR sequencing. Option E incorrectly requires exhaustion of all conventional options. NHS eligibility and commissioning requirements must additionally be observed in UK practice.

Reference: Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update, recommendation on treatment escalation after inadequate hydroxychloroquine response or inability to taper glucocorticoids. 2023. https://www.eular.org/document/download/724/fe9e2ce7-b682-4f2f-aa41-7983eeb7a05c/697